Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
37 Items
Title  Creator  Group name  Publishing year 
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study Adenis et al. EquipeMY 2024-09
The landscape of cancer-associated fibroblasts in colorectal cancer liver metastases Giguelay et al. EquipePM 2022
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial Cousin et al. EquipeMY 2022-02
Poorly cohesive cells gastric carcinoma including signet-ring cell cancer: Updated review of definition, classification and therapeutic management Drubay et al. EquipeMY 2022-08-15
Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma Quesada et al. EquipeMY 2022-01
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma Doki et al. EquipeMY 2022-02-03
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study André et al. EquipeMY 2022-08-15
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181 Adenis et al. EquipeMY 2022-02-01
Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study Bertaut et al. EquipeMY 2022-06
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe Kroese et al. EquipeMY 2022-03
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial Ychou et al. EquipeMY 2022-05
Association of neutrophil extracellular traps with the production of circulating DNA in patients with colorectal cancer Pastor et al. EquipeMY 2022-02-18
Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment Pastor et al. EquipeMY 2021-09
[Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?] Adenis et al. EquipeMY Jan 21, 2020
Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27) Samalin et al. EquipeMY May 15, 2020
Machine Learning-Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer Screening Tanos et al. EquipeCTCS 2020-09
The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma Lutz et al. EquipeMY Mar 14, 2019
Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy Mazard et al. EquipeMY May 10, 2019
Quantifying circulating cell-free DNA in humans Meddeb et al. EquipeMY Mar 26, 2019
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study Randrian et al. EquipeMY Dec 30, 2019
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer Kato et al. EquipeMY Apr 2019
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study Borg et al. EquipeJPP 2019-09
Definitive Chemoradiotherapy for Esophageal Squamous Cell Cancer: A Matter of Standard Adenis et al. EquipeMY Sep 10, 2019
The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers Mariette et al. EquipeMY 02 06, 2018
Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer Adenis and Lordick EquipeMY Jun 01, 2018
12>>>
37 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés